WO1997028255B1 - Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer - Google Patents
Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancerInfo
- Publication number
- WO1997028255B1 WO1997028255B1 PCT/US1997/001430 US9701430W WO9728255B1 WO 1997028255 B1 WO1997028255 B1 WO 1997028255B1 US 9701430 W US9701430 W US 9701430W WO 9728255 B1 WO9728255 B1 WO 9728255B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immortalized
- epithelial cell
- cell line
- prostate epithelial
- malignant
- Prior art date
Links
- 210000000064 prostate epithelial cell Anatomy 0.000 title claims abstract 27
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000003211 malignant effect Effects 0.000 claims abstract 21
- 210000004027 cell Anatomy 0.000 claims abstract 11
- 210000000349 chromosome Anatomy 0.000 claims 8
- 230000002163 immunogen Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000013256 coordination polymer Substances 0.000 claims 3
- 230000000139 costimulatory effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940030749 prostate cancer vaccine Drugs 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100023057 Neurofilament light polypeptide Human genes 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008348 humoral response Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000017095 negative regulation of cell growth Effects 0.000 claims 1
- 108010090677 neurofilament protein L Proteins 0.000 claims 1
- 229940124606 potential therapeutic agent Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract 2
- 206010061764 Chromosomal deletion Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
Abstract
The present invention relates to immortalized, malignant, human, adult prostate epithetial cell lines or cell lines derived therefrom useful in the diagnosis and treatment of prostate cancer. More particularly, the present invention relates to cloned, immortalized, malignant, human, adult prostate epithelial cell lines and uses of these cell lines for the diagnosis and treatment of cancer. Furthermore, the present invention provides for the characterization of said cell lines through the analysis of specific chromosomal deletions.
Claims
55 AMENDED CLAIMS
[received by the International Bureau on 25 July 1997 (25 07 97), oπginal claims 2, 23. 27, 29, 34, 36 and 39 amended, original claim 1 cancelled, remaining claims unchanged (4 pages)]
2. An isolated immortalized, malignant, human, adult prostate epithelial cell line characterized as having at least one allelic loss of heterozygosity.
3. The immortalized, malignant, human, adult prostate epithelial cell line according to claim 2, wherein the allelic loss is at one or more chromosomes.
4. The immortalized, malignant, human, adult prostate epithelial cell line according to claim 3, wherein the chromosomes are selected from the group consisting of: chromosome 1, chromosome 8, chromosome 10, chromosome 16, and combinations thereof.
5. The immortalized, malignant, human prostate epithelial cell line according to claim 2, wherein the allelic loss is on chromosome 8p.
6. The immortalized, malignant, human prostate epithelial cell line according to claim 2, wherein the allelic loss is on chromosome 8p 11-21. 7. The immortalized, malignant, human prostate epithelial cell line according to claim 2, wherein the allelic loss is at more than one locus.
8. The immortalized, malignant cell line according to claim 6, wherein the loss occurs at a locus selected from the group consisting of SFTP-2, D8S133, D8S136, D8S131 , NEFL, D8S137, D8S339, ANK and combinations thereof.
9. A cloned, immortalized malignant prostate epithelial cell line having the identifying characteristics of a cloned, immortalized, malignant prostate epithelial cell line 1535-CP, TX.14.3 deposited as ATCC CRL-12263 with the ATCC. 10. A cloned, immortalized, malignant prostate epithelial cell line having the identifying characteristics of a cloned, immortalized, malignant prostate epithelial cell line 1542-CP3TX.8.4 deposited as ATCC CRL-12264 with the ATCC.
56
22. An immortalized, normal human adult prostate epithelial cell line 1542-NPTX deposited as CRL- 12040 with the ATCC.
23. A composition comprising:
A) an immortalized malignant human adult prostate epithelial cell characterized as having at least one allelic loss of heterozygosity, and
B) an autologous immortalized, normal human adult prostate epithelial cell.
24. The composition according to claim 23 wherein the immortalized malignant human adult prostate epithelial cell line is 1532-CP2TX deposited as CRL- 12038 with the ATCC and the autologous immortalized, normal human adult prostate epithelial cell line is 1532-NPTX deposited as CRL- 12036 with the ATCC.
25. The composition according to claim 23 wherein the immortalized malignant human adult prostate epithelial cell line is 1535-CP,TX deposited as CRL-12041 with the ATCC and the autologous immortalized, normal human adult prostate epithelial cell line is 1535-NPTX deposited as CRL- 12039 with the ATCC.
26. The composition according to claim 23 wherein the immortalized, malignant human adult prostate epithelial cell line is 1542-CP3TX deposited as CRL 12037 with the ATCC and the autologous immortalized, normal human adult prostate epithelial cell line is 1542-NPTX deposited as CRL- 12040 with the ATCC.
27. A pharmaceutical composition comprising an immortalized, human, adult, prostate epithelial cell line, clone, or portion thereof according to claims 2-22 and a pharmaceutically acceptable carrier.
57
28. The pharmaceutical composition according to claim 27 further comprising an adjuvant, costimulatory molecule, cytokine, chemokine, adhesion molecule, an MHC molecule or combination thereof.
29. An immunogen for eliciting an immune response specific for a prostate cancer protein or portion thereof comprising an immortalized, human, adult, prostate epithelial cell line, clone or immunogenic portion thereof, according to claims 2-22.
55
58
30. The immunogen according to claim 29 further comprising an adjuvant, cytokine, costimulatory molecule, chemokine, adhesion molecule, an MHC molecule or combination thereof.
31. The immunogen according to claim 29, wherein the immune response is a cell mediated response.
32. The immunogen according to claim 29, wherein the immune response is humoral response.
33. An antibody immunoreactive with the immunogen according to claim 29. 34. A prostate cancer vaccine comprising an immortalized, malignant, human, adult, prostate epithelial cell line or clone according to claims 2-22 or portion thereof.
35. The prostate cancer vaccine according to claim 34, further comprising one or more genes encoding cytokines, chemokines, costimulatory molecules, adhesion molecules, or MHC molecules incorporated into said cell.
36. A method of screening for a potential therapeutic agent comprising exposing an immortalized, adult, prostate epithelial cell according to claims 2-22 to the agent to be tested and assessing the effect of the agent on the cell. 37. The method according to claim 36, wherein the effect is cytotoxicity.
38. The method according to claim 36, wherein the effect is inhibition of cell growth.
39. A kit comprising at least one immortalized, adult, prostate epithelial cell line according to claims 2-22.
40. The kit according to claim 39 wherein the kit comprises:
A) an immortalized normal cell line and,
B) an immortalized malignant cell line, wherein the normal and malignant cell lines are derived from the same individual. 41. Method of selecting an immortalized malignant, human, adult prostate epithelial cell line from a source comprising:
8255
59
STATEMENT UNDER ARTICLE 19
Claim 1 on replacement sheet 50/1 is cancelled.
Amended claim 2 on replacement sheet 50/1 differs from the original claim 2 in that - isolated ~ has been inserted after recitation of "An" in line 1 and the recitation of [according to claim 1] in line 2 has been deleted.
Amended claim 22 on replacement sheet 52/1 differs from the original claim 22 in that the phrase ~ characterized as having at least one allelic loss of heterozygosity - has been added in line 3.
Amended claim 27 on replacement sheet 52/1 differs from the original claim 27 in that the phrase " 1-22" has been changed to - 2-22 - in line 3. Amended claim 29 on replacement sheet 52/2 differs from the original claim 29 in that the phrase " 1-20" has been changed to ~ 2-22 ~ in line 4.
Amended claim 34 on replacement sheet 53/1 differs from the original claim 34 in that the phrase "1-22" has been changed to ~ 2-22 - in line 3.
Amended claim 36 on replacement sheet 53/1 differs from the original claim 36 in that the phrase "1-22" has been changed to - 2-22 - in line 3.
Amended claim 39 on replacement sheet 53/1 differs from the original claim 39 in that the phrase " 1-22" has been changed to - 2-22 - in line 2.
Applicant respectfully submits that the amendment to the claims does not introduce new matter and are fully supported by the description and drawings.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002245099A CA2245099C (en) | 1996-02-02 | 1997-01-30 | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
| JP9527794A JP2000506379A (en) | 1996-02-02 | 1997-01-30 | Cell lines and clones of human prostate epithelial immortal cells and their research and application for prostate cancer treatment |
| AT97904061T ATE239781T1 (en) | 1996-02-02 | 1997-01-30 | IMMORTALIZED HUMAN PROSTATE EPITHELIAL CELLS AND CLONES AND THEIR USES IN THE STUDY AND THERAPY OF PROSTATE CANCER |
| DE69721731T DE69721731T2 (en) | 1996-02-02 | 1997-01-30 | IMMORTALIZED HUMAN PROSTATE EPITHELIC CELLS AND CLONES AND THEIR USE FOR THE EXAMINATION AND THERAPY OF PROSTATE CANCER |
| US08/913,770 US6982168B1 (en) | 1996-02-02 | 1997-01-30 | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
| EP97904061A EP0877798B1 (en) | 1996-02-02 | 1997-01-30 | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1104296P | 1996-02-02 | 1996-02-02 | |
| US60/011,042 | 1996-02-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997028255A1 WO1997028255A1 (en) | 1997-08-07 |
| WO1997028255B1 true WO1997028255B1 (en) | 1997-09-18 |
Family
ID=21748614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/001430 WO1997028255A1 (en) | 1996-02-02 | 1997-01-30 | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6982168B1 (en) |
| EP (1) | EP0877798B1 (en) |
| JP (2) | JP2000506379A (en) |
| AT (1) | ATE239781T1 (en) |
| AU (1) | AU755554B2 (en) |
| CA (1) | CA2245099C (en) |
| DE (1) | DE69721731T2 (en) |
| WO (1) | WO1997028255A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9827102D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| GB9827103D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| AU4935700A (en) * | 1999-05-21 | 2000-12-12 | Onyvax Limited | New vaccine formulations-3 |
| EP1178822B1 (en) * | 1999-05-21 | 2004-02-18 | Onyvax Limited | Whole cell cancer vaccine comprising co-cultured malignant and non-malignant cells |
| GB9911823D0 (en) * | 1999-05-21 | 1999-07-21 | Onyvax Ltd | New vaccine formulations |
| AU2001244341A1 (en) * | 2000-04-01 | 2001-10-15 | Onyvax Limited | New prostate cell lines |
| US20050019336A1 (en) * | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
| WO2005083060A1 (en) | 2004-03-01 | 2005-09-09 | Kitakyushu Foundation For The Advancement Of Industry, Science And Technology | Human cell strains for protein production, provided by selecting strains with high intracellular protein and mutating with carcinogens |
| WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
| US8715732B2 (en) * | 2009-01-05 | 2014-05-06 | Cornell University | Nucleic acid hydrogel via rolling circle amplification |
| US20130219531A1 (en) * | 2011-08-19 | 2013-08-22 | Tuskegee University | Immortalized human prostate cell lines |
| JP6877550B2 (en) * | 2016-12-22 | 2021-05-26 | ヴェンタナ メディカル システムズ， インク． | Fully automatic nucleic acid extraction method for tissue samples |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443954A (en) | 1987-10-30 | 1995-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Immortalized non-tumorigenic human bronchial epithelial cell lines |
| US5026637A (en) | 1989-02-28 | 1991-06-25 | Herbert Soule | Immortal human mammary epithelial cell lines |
| GB9105532D0 (en) | 1991-03-15 | 1991-05-01 | Imutran Ltd | Antibody production |
| US5376542A (en) | 1992-04-27 | 1994-12-27 | Georgetown University | Method for producing immortalized cell lines using human papilluma virus genes |
| US5462870A (en) | 1993-04-23 | 1995-10-31 | Wayne State University | Human diploid salivary gland epithelial cell lines |
| US5610043A (en) | 1994-04-28 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus |
| US5824488A (en) * | 1994-04-28 | 1998-10-20 | Board Of Trustees Operating Michigan State University | Immortalized and malignant human prostatic cell lines |
-
1997
- 1997-01-30 DE DE69721731T patent/DE69721731T2/en not_active Expired - Lifetime
- 1997-01-30 WO PCT/US1997/001430 patent/WO1997028255A1/en active IP Right Grant
- 1997-01-30 JP JP9527794A patent/JP2000506379A/en active Pending
- 1997-01-30 AT AT97904061T patent/ATE239781T1/en not_active IP Right Cessation
- 1997-01-30 CA CA002245099A patent/CA2245099C/en not_active Expired - Fee Related
- 1997-01-30 EP EP97904061A patent/EP0877798B1/en not_active Expired - Lifetime
- 1997-01-30 US US08/913,770 patent/US6982168B1/en not_active Expired - Fee Related
-
1998
- 1998-07-24 AU AU77493/98A patent/AU755554B2/en not_active Ceased
-
2005
- 2005-11-10 JP JP2005326161A patent/JP2006122052A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Razin et al. | Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. | |
| Pluznik et al. | The induction of clones of normal mast cells by a substance from conditioned medium | |
| van den Eijnden-Van Raaij et al. | Activin-like factor from a Xenopus laevis cell line responsible for mesoderm induction | |
| WO1997028255B1 (en) | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer | |
| Kopelovich et al. | Tumour promoter alone induces neoplastic transformation of fibroblasts from humans genetically predisposed to cancer | |
| Watt et al. | Stratification and terminal differentiation of cultured epidermal cells | |
| Grabstein et al. | Regulation of T cell proliferation by IL-7. | |
| DE60208692T2 (en) | INTERLEUKIN -18 MUTANT PROTEINS, THEIR PREPARATION AND USE | |
| AU676891B2 (en) | Pharmaceutical containing the P40 subunit of interleukin 12 | |
| AU4306896A (en) | Method for the preparation of a viral vector by intermolecular homologous recombination | |
| JPH08231593A (en) | Tumor growth inhibitory factor and method for preparing the same | |
| Grabner et al. | Corneal epithelial cell--derived thymocyte-activating factor (CETAF). | |
| Jami et al. | Lack of expression of differentiation in mouse teratoma-fibroblast somatic cell hybrids | |
| EP0693120B1 (en) | Tumoricide t lymphocytes | |
| HK1007922A1 (en) | Immunomodulating compositions from bile | |
| DE69721731T2 (en) | IMMORTALIZED HUMAN PROSTATE EPITHELIC CELLS AND CLONES AND THEIR USE FOR THE EXAMINATION AND THERAPY OF PROSTATE CANCER | |
| DE19740571C1 (en) | Antigen-specific stimulation of T cells | |
| CA2254082A1 (en) | Metastatic colorectal cancer vaccine | |
| WO1999025812A1 (en) | Method for the production and use of dendritic cells | |
| Guillaudeux et al. | In situ hybridization localizes the human OTF3 to chromosome 6p21. 3→ p22 and OTF3L to 12p13 | |
| Yoshikawa et al. | Enkephalin precursor gene expression in postmeiotic germ cells | |
| Yeger et al. | Phenotypic and molecular characterization of inducible human neuroblastoma cell lines | |
| ATE248914T1 (en) | ALLOGENE VACCINE AND SYNTHESIS METHOD FOR THE SAME | |
| KR101913353B1 (en) | Immuno-suppressive dendritic cell-like cell and manufacturing method thereof | |
| Morrison et al. | A simple method of generating axenic derivatives of Dictyostelium strains |